Meriden, Conn--A 5-year study at Walter Reed Army Institute of
Research found no significant clinical benefit for patients receiving
MicroGenesys, Inc's therapeutic AIDS vaccine,VaxSyn rpg 160,compared
with placebo, the company has announced.
Preiminary analysis of data from the phase II study, conducted
in more than 600 HIV-infected volunters, demonstrated the saftey
of VaxSyn. According to the company, these data indicate that
MicroGeneSys's proprietary baculovirus expression vector system
(BEVS) is a safe process for manufacturing human biologics that
are to be used in large numbers of patients receiving frequent
injections over a long period of time.
"Although there were no statistically significant differences
in clinical events,there were certain modest and time limited
effects favoring VaxSyn. Further data analysis are being done
that may show that some groups of patients may have responded
favorably to treatment with VaxSyn," the company said.